Your competitor isn’t “improving” the drug. They’re extending it. Here are 4 signals to watch.
In pharma, the most expensive word in the room is often the quietest one: extension.
A competitor doesn’t need to invent a brand-new product to protect reven…

Biopharma teams don’t lose deals because they can’t pitch. They lose because they pitch too early—or too late.
In licensing, partnering, and BD strategy, timing is everything. But in drug development and commercialization, timing isn’t just about clini…

OpenAI’s “GPT for Life Sciences” is getting a lot of attention—but the real question for investors, pharma leaders, and biotech operators isn’t whether the model is impressive. It’s what it actually changes in the drug development value chain.
Because …

Fatigue is a common side effect of Lipitor, a medication used to lower cholesterol levels and prevent heart disease. According… https://www.Drugchatter.com/chat/16688/do-you-often-feel-tired-after-taking-lipitor/

Yervoy, also known as ipilimumab, is a medication used to treat melanoma. It has been on the market since March 2011 and… https://www.Drugchatter.com/chat/23203/any-news-on-yervoy-s-patent-expiration/

Patent expiry intelligence isn’t just for lawyers—it’s for operators.
Most biosimilar strategies fail in the same place: timing. Not the timing of regulatory filings or the timing of clinical plans—the timing of manufacturing decisions.
If you’re w…

Drug patent protection in Europe: the clock starts ticking the moment you file—and it doesn’t stop when you want it to.
If you’re building a pipeline, funding a launch, or underwriting a deal, the real question isn’t “Do we have patent protection?” It’…

Drug discovery timelines are getting longer—until you redesign the workflow.
For years, the industry has treated “time” like an unavoidable cost of doing science: target identification takes months, lead optimization takes years, and regulatory-grade…

The “Patent Expiration Cliff” Isn’t a Cliff—It’s a Calendar Problem. Here’s How Commercial Market Access Teams Can Stop Getting Surprised.
If you’ve ever watched a brand’s revenue trajectory bend sharply overnight—right when exclusivity ends—you alread…

Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits
If you’ve ever watched a first-filer launch turn into a slower-than-expected climb, there’s a quiet reason that shows up again and again: authorized generics.
In plain terms…